Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study.

Haynes BF, Kelsoe G, Harrison SC, Kepler TB.

Nat Biotechnol. 2012 May 7;30(5):423-33. doi: 10.1038/nbt.2197.

2.

Antibody polyspecificity and neutralization of HIV-1: a hypothesis.

Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM.

Hum Antibodies. 2005;14(3-4):59-67. Review.

3.

Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.

Sadanand S, Suscovich TJ, Alter G.

Annu Rev Med. 2016;67:185-200. doi: 10.1146/annurev-med-091014-090749. Epub 2015 Nov 9. Review.

PMID:
26565674
4.

Broadly neutralizing antibodies against HIV-1: templates for a vaccine.

van Gils MJ, Sanders RW.

Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Review.

5.

Bioorganic approaches towards HIV vaccine design.

Wang LX.

Curr Pharm Des. 2003;9(22):1771-87. Review.

PMID:
12871196
6.

HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.

Sliepen K, Sanders RW.

Expert Rev Vaccines. 2016;15(3):349-65. doi: 10.1586/14760584.2016.1129905. Epub 2016 Jan 8. Review.

PMID:
26654478
7.

GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.

PMID:
16551265
8.

Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.

GeiƟ Y, Dietrich U.

AIDS Rev. 2015 Apr-Jun;17(2):107-13. Review.

PMID:
26035168
9.

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Montero M, van Houten NE, Wang X, Scott JK.

Microbiol Mol Biol Rev. 2008 Mar;72(1):54-84, table of contents. doi: 10.1128/MMBR.00020-07. Review.

10.

On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development?

Parsons MS, Muller S, Kohler H, Grant MD, Bernard NF.

Hum Vaccin Immunother. 2013 Jul;9(7):1532-8. doi: 10.4161/hv.24460. Epub 2013 Apr 9. Review.

PMID:
23571168
11.

HIV-1 vaccine development: tackling virus diversity with a multi-envelope cocktail.

Hurwitz JL, Zhan X, Brown SA, Bonsignori M, Stambas J, Lockey TD, Sealy R, Surman S, Freiden P, Jones B, Martin L, Blanchard J, Slobod KS.

Front Biosci. 2008 Jan 1;13:609-20. Review.

PMID:
17981574
12.

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT.

Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819. Review.

PMID:
18197170
13.

The role of antibodies in HIV vaccines.

Mascola JR, Montefiori DC.

Annu Rev Immunol. 2010;28:413-44. doi: 10.1146/annurev-immunol-030409-101256. Review.

PMID:
20192810
14.

Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.

Chen W, Ying T, Dimitrov DS.

Expert Opin Biol Ther. 2013 May;13(5):657-71. doi: 10.1517/14712598.2013.761969. Epub 2013 Jan 7. Review.

PMID:
23293858
15.
16.

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Verkoczy L, Kelsoe G, Moody MA, Haynes BF.

Curr Opin Immunol. 2011 Jun;23(3):383-90. doi: 10.1016/j.coi.2011.04.003. Epub 2011 Apr 27. Review.

17.

Virological features associated with the development of broadly neutralizing antibodies to HIV-1.

Moore PL, Williamson C, Morris L.

Trends Microbiol. 2015 Apr;23(4):204-11. doi: 10.1016/j.tim.2014.12.007. Epub 2015 Jan 5. Review.

18.

Immunologic Basis for Long HCDR3s in Broadly Neutralizing Antibodies Against HIV-1.

Yu L, Guan Y.

Front Immunol. 2014 Jun 2;5:250. doi: 10.3389/fimmu.2014.00250. eCollection 2014. Review.

Supplemental Content

Support Center